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Introduction: Ganglioneuromas are rare benign tumors arising from the neural crest tissue and are most
commonly located in the posterior mediastinum and retroperitoneum; they are rarely found in the adrenal gland.
This tumor is usually asymptomatic and in the majority of cases is detected incidentally. Although the
characteristics of adrenal ganglioneuroma on computerized tomography and magnetic resonance imaging have
been well described, the exact diagnosis is difficult. Histopathological examination is currently the mainstay of
diagnosis. Ganglioneuromas have a very good prognosis with surgical removal. We report the case of a male
patient with an incidentally identified adrenal ganglioneuroma with high standardized uptake values in a positron
emission tomography scan.
Case presentation: An 18-year-old Turkish male patient with no previous comorbidities was admitted to our
hospital with lower-quadrant pain. He had no significant past medical or surgical history. A physical examination
did not reveal any signs and the results of routine laboratory tests were all within the normal ranges. Our patient
underwent computed tomography of his abdomen, which showed a relatively homogenous left adrenal tumor
measuring 5.2×4.3×7.1cm. On a positron emission tomography scan, the left adrenal gland disclosed a standardized
uptake value of 4.1. Our patient underwent an exploratory laparotomy with left adrenalectomy without any related
complications.
Conclusion: Ganglioneuroma may sometimes be similar to other adrenal malignancies. Careful evaluation with
endocrine tests and imaging procedures is necessary to provide an accurate diagnosis. Definitive diagnosis can
be made by histological examination. The prognosis is very good with surgical removal.
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Ganglioneuroma (GN) is a rare benign tumor arising
from the neural crest tissue and most commonly located
in the posterior mediastinum and retroperitoneum. GN’s
are rarely found in the adrenal gland [1,2]. This tumor is
usually asymptomatic and, in the majority of cases, de-
tected incidentally. Now that imaging procedures such
as ultrasonography and computerized tomography (CT)
are used more frequently, this unexpected and excep-
tional incidentaloma lesion can be detected more easily
[3,4]. The prevalence of adrenal incidentaloma is 0.2% in
young patients, 3% in populations past their fifth decade,
and as high as 7% in those past their seventh decade [5].* Correspondence: drborakoc@hotmail.com
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active, some of them secrete catecholamines. Symptoms
like hypertension, diarrhea and virilization may develop
as a result of mixed hormone secretion; in such case the
diagnosis will be controversial. Tumors that originate from
the ganglion cells include GN (benign), ganglioneuroblas-
toma (intermediate differentiation) and neuroblastoma
(highly malignant lesion). The imaging characteristics of
adrenal GN are variable and some are very similar to other
adrenal tumors such as adrenocortical carcinoma (ACC)
and pheochromocytoma, a fact that is crucial in the clinic
[4,6]. Therefore, it is generally challenging to obtain a
precise differential diagnosis of adrenal GN prior to sur-
gery. A definitive diagnosis can be made by histological
examination.
In this case report, we present the case of an 18-year-
old male patient with an adrenal tumor. The tumor wasd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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during an evaluation of his right lower-quadrant pain.
Case presentation
An 18-year-old Turkish male patient with no previous
comorbidities was admitted to our hospital with right
lower-quadrant pain. He had no significant past medical
or surgical history. A physical examination revealed no
signs and the results of routine laboratory tests were all
found to be within the normal ranges. Because of his
symptoms, an abdominal ultrasound was performed and
showed a heterogeneous, well-defined mass measuring
5×7cm at his left adrenal gland. Our patient was referred
to the endocrinology department where he underwent
abdominal CT, which showing a relatively homogenous
left adrenal tumor measuring 5.2×4.3×7.1cm with faint
calcification and well-defined edges. Magnetic resonance
imaging (MRI) showed a solid mass measuring 5×4×7cmFigure 1 Positron emission tomography and computerized tomograp
deoxy-D-glucose-positron emission tomography scans show a standard up
(arrow shows the mass on computed tomography).arising from his left adrenal gland. The tumor was
slightly hypointense on T1A-weighted MRI, whereas it
was slightly hyperintense on T2A-weighted MRI. After
an intravenous injection of gadolinium, the mass showed
a progressive, heterogeneous and delayed enhancement.
An endocrine workup, including urine catecholamine
and cortisol levels and a 1mg overnight dexamethasone
suppression test, was normal. Because of the tumor size,
we performed an 18F-2-fluoro-deoxy-D-glucose-positron
emission tomography (PET) scan to diagnose the malig-
nant lesion. His left adrenal gland showed a standardized
uptake value (SUV) of 4.1 (Figure 1). With these find-
ings, it was not possible to conclude whether the adrenal
tumor was benign or malignant.
For this reason, exploratory laparotomy was performed
to allow a definite diagnosis. A left adrenalectomy was
performed, with no related complication. The surgical
specimen was an elastic tumor with a slightly lobularhy scans of the patient with a left adrenal tumor. 18F-2-fluoro-
take value of 4.1 for a left adrenal mass measuring 5.2×4.3×7.1cm.
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face of the tumor was light brown, covered by a thin
capsule without any evidence of hemorrhage or necrosis.
On microscopy, the section showed irregular prolifera-
tion of spindle-shaped cells and scattered mature gangli-
onic cells with dystrophic changes and focal lymphocytic
infiltration. No evidence was found for the malignancy.
An immunohistochemical examination showed positive
staining of the ganglion and Schwann cells for S-100,
vimentin and synaptophysin (Figure 3). The tumor was di-
agnosed as a left adrenal GN. Our patient experienced no
complications during his postoperative course. No recur-
rence was detected during the one-year follow-up visits.
Discussion
GN is a rare, differentiated and benign tumor arising
from primordial neural crest cells that form the sympa-
thetic nervous system [7]. On histology, it is composed
of mature Schwann cells and ganglion cells with fibrous
stroma [1,8]. GN is a member of a group of neurogenic
tumors group that includes ganglioblastoma and neuro-
blastoma. It differs from other neurogenic tumors in
its benign potential [7]. These non-functional and non-
symptomatic masses are usually detected incidentally
and are referred to as incidentaloma. Because of the im-
provements in CT and ultrasonography procedures, the
number of incidentalomas found has recently increased.
The pathology of adrenal incidentalomas may vary
from a simple benign cyst or lipoma to adrenal carcin-
oma. The differential diagnosis of an adrenal mass com-
prises a long list including adenoma, myelolipoma, cyst,Figure 2 Macroscopic view of the specimen. Surgical specimen
was an elastic tumor with a slightly lobular edge, measuring
4.4×5.1×7.3cm.lipoma, pheochromocytoma, adrenal cancer, metastatic
cancer, hyperplasia and tuberculosis [1-8]. Functioning
tumors and carcinomas are not generally discovered in-
cidentally because their diagnosis is based on specific
signs and symptoms. It should be noted that some func-
tional tumors may present a subclinical form without
any specific symptoms and some malignant tumors may
look like benign lesions in radiological evaluations. The
diagnosis of an adrenal tumor as a pheochromocytoma
depends on the ability to determine its catecholamine
content by biochemical or histochemical methods. Al-
though extra-adrenal tumors have also been designated
as pheochromocytomas by some authors, the preferred
terminology for such neoplasms is ‘extra-adrenal para-
ganglioma’. Terms such as ‘composite pheochromocyto-
mas’ and ‘compound tumor of the adrenal medulla’ have
been used to describe tumors containing pheochromocy-
toma together with foci of neuroblastoma, ganglioneuro-
blastoma, GN or malignant peripheral nerve sheath
tumor [9]. Literature shows that about 71% of composite
pheochromocytoma or paraganglioma coexist with GN.
Like ordinary pheochromocytomas and paragangliomas,
most cases of composite pheochromocytomas or para-
gangliomas were functional, with increased levels of cat-
echolamines or corticotropin-releasing hormone [10].
Although GN is generally considered to occur more
frequently in young people, some recent studies have
shown that it may also be seen between the ages 40 and
50 [4,11]. GN is most commonly found in the posterior
mediastinum and retroperitoneum, and the involvement
of the adrenal gland is relatively rare (21%) [12]. Adrenal
GN is usually regarded as having silent hormonal func-
tions and therefore can be asymptomatic. Occasionally,
composite tumors with pheochromocytoma are seen and
they, rarely, can secrete cortisol and androgen [13,14].
Additionally, Geoerger et al. reported that up to 30% of
patients with GN had elevated plasma and urinary cat-
echolamine levels but that patients were rarely found to
have symptoms of catecholamine excess [1]. By contrast,
Koch et al. reported the case of a patient with a GN that
was positive for vasoactive intestinal peptide, which is
the product of ganglion cells [15]. Patients with vaso-
active intestinal peptide-positive tumors such as GN and
neuroblastomas may not have any symptoms or signs of
vasoactive intestinal peptide secretion [16]. GN can also
produce and secrete other hormones, such as testoster-
one, indicating the pluripotency of its precursor cell.
In our patient, his tumor was hormonally inactive and
asymptomatic [17].
GN is a benign neoplasm that originates from neural
crest cells of sympathetic ganglia or adrenal medulla. The
macroscopic characteristics of adrenal GN are an encap-
sulated mass with a firm consistency and a solid, ho-
mogeneous, grayish-white cut surface. Histopathological
Figure 3 Immunohistochemical examination of the mass. (a) Positive staining for vimentin, ×200. (b) Positive staining for synaptophysin, ×200.
(c) Pattern of nerve bundles in the neoplasm with vesicular nucleus and huge ganglion cells including wide cytoplasm. Hematoxylin and eosin
staining, ×40. (d) Ganglion cell group in detail. Hematoxylin and eosin staining, ×100.
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cells among a fibrous stroma. Using microscopy they can
be classified in two main groups: mature and maturing.
The mature type is composed of mature Schwann cells,
ganglion cells and perineurial cells, whereas the maturing
type consists of cells with different maturation levels, ran-
ging from mature cells to neuroblasts with a similar
stroma. According to immunohistochemical analysis, GN
are characterized by reactivity for S-100, vimentin, synap-
tophysin and neuronal markers [14]. In our patient, a final
pathological examination confirmed the diagnosis.
Although the imaging characteristic of adrenal GN on
CT and MRI have been well described, the precise diag-
nosis of adrenal GN using radiological evaluation prior
to surgery is difficult. Qing et al. reported that the mis-
diagnosis rate of adrenal GN on CT and MRI before
surgery is 64.7% [4]. Adrenal GN is described as a well-
circumscribed tumor with lobular shape and low atte-
nuation. In the literature, intratumoral calcification has
been determined in 0% to 29% of the cases [4,6]. On
MRI, adrenal GN shows homogenously low or inter-
mediate signal intensity in T1-weighted images and het-
erogeneous slightly high signal intensity on T2-weighted
images [14]. For a tumor size larger than 5cm, hetero-
geneity and calcification may suggest malignancy [18]. In
our patient, because the size and heterogeneity of the
mass made us suspect malignancy, we preferred to per-
form a PET scan prior to the surgery.
PET scans can help complete the picture obtained by
CT and MRI when making a differential diagnosis bet-
ween adrenal GN and ACC or metastasis. One studyreported that all cases of ACC had a SUV of 3.0 or
higher, and that the sensitivity and specificity to distin-
guish ACC from adenoma were 100% and 98%, respec-
tively [19,20]. In another review of four patients with
adrenal GN, the SUVs were between 1.5 and 2.9 [11].
The SUV in our case was 4.1, which also suggested
ACC. A PET scan is one of the most helpful modalities
to differentiate malignancy and adenoma. However, in
rare cases it may still mislead the physicians.
Even though a lesion size greater than 4.5cm seems to
be a strong predictor of malignancy, this is not correctly
confirmed by histologic evaluations. In our patient, al-
though his tumor was larger than 6cm and the SUV
level on PET was above than 3.0, pathology confirmed a
benign tumor. Recent studies recommended that non-
secretary adrenal incidentalomas larger than 6cm or
with suspicious features of malignancy on imagining
procedures should be treated by adrenalectomy [3-7].
There is no medical treatment for such tumors. GN, al-
though benign, can grow aggressively. Patients treated
surgically for a benign neurogenic tumor have an excel-
lent prognosis. Papavramidis et al. reported that adrenal
GN should be resected by adrenalectomy, whereas retro-
peritoneal GN can be resected without adrenalectomy
[21]. The role of laparoscopic adrenalectomy in patients
with large adrenal lesions or potential malignancy
remains controversial. The reduced hospital stay and
morbidity have resulted in laparoscopic adrenalectomy be-
coming the procedure of choice for the surgical removal
of a vast majority of small sized (<6cm) adrenal lesions
[1,3,7]. The prognosis for an adrenal GN following surgical
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ment. A few cases of recurrence have been reported.
Long-term follow-up is recommended.
Conclusion
An adrenal GN is a rare, hormonally silent benign tumor.
GN can sometimes resemble other adrenal malignancies.
Careful evaluation by endocrine tests and imaging proce-
dures is necessary for an accurate diagnosis. A definitive
diagnosis can be made by histological examination. The
prognosis is very good with surgical removal.
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